UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR QUARTER ENDED DECEMBER 31, 2001 Commission File Number 0-10248
FONAR CORPORATION
------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 11-2464137
- -------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
110 Marcus Drive Melville, New York 11747
- ---------------------------------------- --------------------------------
(Address of principal executive offices) (Zip Code)
(631) 694-2929
------------------------------
Registrant's telephone number,
including area code:
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES X NO
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the close of the period covered by this report.
Class Outstanding at December 31, 2001
- -------------------------------- --------------------------------
Common Stock, par value $.0001 61,570,097
Class B Common Stock, par value $.0001 4,211
Class C Common Stock, par value $.0001 9,562,824
Class A Preferred Stock, par value $.0001 7,836,286
FONAR CORPORATION AND SUBSIDIARIES
INDEX
PART I - FINANCIAL INFORMATION PAGE
Item 1. Financial Statements
Condensed Consolidated Balance Sheets - December 31, 2001
and June 30, 2001 3
Condensed Consolidated Statements of Operations for
the Three Months Ended December 31, 2001 and
December 31, 2000 5
Condensed Consolidated Statements of Operations for
the Six Months Ended December 31, 2001 and
December 31, 2000 6
Condensed Consolidated Statements of Cash Flows for
the Six Months Ended December 31, 2001 and
December 31, 2000 7
Condensed Consolidated Statements of Comprehensive
Income (Loss) for the Six Months Ended December 31, 2001
and December 31, 2000 8
Notes to Condensed Consolidated Financial Statements 9
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
PART II - OTHER INFORMATION
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
ASSETS December 31, June 30,
2001 2001
(UNAUDITED)
Current Assets: ------------ ---------
Cash and cash equivalents $ 5,759 $14,040
Marketable securities 6,137 6,085
Accounts receivable - net 1,063 850
Accounts receivable - related medical practices - net 12,085 13,181
Costs and estimated earnings in excess
of billings on uncompleted contracts 1,303 1,769
Inventories 4,703 3,725
Investment in sales-type leases - related parties 195 191
Investment in sales-type lease 112 120
Prepaid expenses and other current assets 1,372 904
-------- --------
Total current assets 32,729 40,865
-------- --------
Restricted cash 5,500 5,500
Property and equipment - net 9,733 10,637
Advances and notes to related parties - net 2,824 1,559
Investment in sales-type leases - related parties 2,480 2,514
Investment in sales-type lease 803 861
Notes receivable - net 375 375
Management agreements - net 19,829 20,438
Other intangible assets - net 1,955 1,854
Other assets 296 297
-------- --------
$76,524 $84,900
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
December 31, June 30,
LIABILITIES AND STOCKHOLDERS' EQUITY 2001 2001
(UNAUDITED)
Current Liabilities: ------------ --------
Current portion of long-term debt and capital
lease obligations $ 6,184 $ 6,635
Accounts payable 2,568 3,021
Other current liabilities 5,954 6,176
Customer advances 2,999 1,672
Billings in excess of costs and estimated
earnings on uncompleted contracts 574 351
Income taxes payable 777 765
Convertible debentures 3,150 4,500
-------- --------
Total current liabilities 22,206 23,120
Long-term debt and capital lease obligations,
less current portion 7,643 10,109
Unearned revenue - license fee 8,190 9,360
Other non-current liabilities 348 327
-------- --------
Total liabilities 38,387 42,916
-------- --------
Minority interest 86 153
-------- --------
Commitments and contingencies - -
STOCKHOLDERS' EQUITY
Common Stock $.0001 par value; 85,000,000 shares
authorized; 61,570,097 and 59,524,455 shares issued;
61,279,033 and 59,233,391 shares outstanding at
December 31, 2001 and June 30, 2001, respectively 6 6
Class B Common Stock $ .0001 par value; 4,000,000
shares authorized, (10 votes per share), 4,211 issued
and outstanding at December 31, 2001 and at
June 30, 2001 - -
Class C Common Stock $.0001 par value; 10,000,000
shares authorizede, (25 votes per share), 9,562,824
issued and outstanding at December 31, 2001 and at
June 30, 2001 1 1
Class A non-voting Preferred Stock $.0001 par value;
8,000,000 authorized, 7,836,287 issued and outstanding
at December 31, 2001 and at June 30, 2001 1 1
Paid-in capital in excess of par value 108,454 104,984
Accumulated other comprehensive income 150 84
Accumulated deficit (68,558) (60,001)
Notes receivable - stockholders ( 838) ( 1,040)
Unearned compensation ( 490) ( 1,529)
Treasury stock - 291,064 shares of common stock
at December 31, 2001 and June 30, 2001 ( 675) ( 675)
-------- --------
Total stockholders' equity 38,051 41,831
-------- --------
Total liabilities and stockholders' equity $76,524 $84,900
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
FOR THE THREE MONTHS ENDED
DECEMBER 31,
--------------------------
2001 2000
REVENUES -------- --------
Product sales - net $ 480 $ 995
Product sales - related parties - net 1,585 -
Service and repair fees - net 539 464
Patient revenue - net - 342
Management and other fees - related medical
practices - net 6,514 7,161
License fees and royalties 648 627
-------- --------
Total Revenues - Net 9,766 9,589
-------- --------
COSTS OF REVENUES:
Cost related to product sales 348 1,180
Cost related to product sales - related parties 1,175 -
Cost related to service and repair fees 619 545
Cost related to patient revenue - 281
Cost related to management and other
fees - related parties 4,349 4,303
Research and development 1,254 1,516
Selling, general and administrative 5,078 4,780
Provision for bad debts 42 -
Compensatory element of stock issuances for
selling, general & administrative expenses 627 637
Amortization of management agreements 305 305
-------- --------
Total Costs and Expenses 13,797 13,547
-------- --------
Loss From Operations ( 4,031) ( 3,958)
Interest Expense ( 207) ( 315)
Financing costs paid in stock and warrants ( 721) -
Investment Income 244 543
Other income (expense) ( 4) 788
Minority interest in (income) loss
of subsidiary and partnerships 19 ( 65)
-------- --------
Loss before provision for income taxes ( 4,700) ( 3,007)
Provision for income taxes 10 7
-------- --------
NET LOSS $( 4,710) $( 3,014)
======== ========
Basic and diluted Net Loss per share $(.07) $(.04)
======== ========
Weighted average number of shares outstanding 72,307 68,273
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
FOR THE SIX MONTHS ENDED
DECEMBER 31,
------------------------
2001 2000
REVENUES -------- --------
Product sales - net $1,516 $ 1,134
Product sales - related parties - net 2,433 118
Service and repair fees - net 1,081 923
Patient revenue - net - 717
Management and other fees - related medical
practices - net 13,657 14,425
License fees and royalties 1,233 1,254
-------- --------
Total Revenues - Net 19,920 18,571
-------- --------
COSTS OF REVENUES:
Cost related to product sales 1,067 1,472
Cost related to product sales - related parties 1,920 343
Cost related to service and repair fees 1,218 1,217
Cost related to patient revenue 597
Cost related to management and other
fees - related parties 8,318 8,512
Research and development 2,460 3,028
Selling, general and administrative 9,820 9,218
Provision for bad debts 185 -
Compensatory element of stock issuances for
selling, general & administrative expenses 1,735 1,533
Amortization of management agreements 609 609
-------- --------
Total Costs and Expenses 27,332 26,529
-------- --------
Loss From Operations ( 7,412) ( 7,958)
Interest Expense ( 562) ( 594)
Financing costs paid in stock and warrants ( 1,015) -
Investment Income 533 1,003
Other income (expense) 16 810
Minority interest in (income) loss
of partnership ( 100) ( 168)
-------- --------
Loss before provision for taxes and
minority interest ( 8,540) ( 6,907)
Provision for income taxes 17 14
-------- --------
NET LOSS $( 8,557) $( 6,921)
======== =======
Basic and Diluted Net Loss per share $(.12) $(.10)
======== ========
Weighted average number of shares outstanding 72,307 68,273
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(000'S OMITTED)
FOR THE SIX MONTHS ENDED
DECEMBER 31,
------------------------
2001 2000
-------- --------
Cash Flows from Operating Activities
Net Loss $( 8,557) $( 6,921)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Minority interest in net income loss of partnerships 100 168
Depreciation and amortization 2,567 2,323
Provision for bad debts 185 -
Stock issued for financing costs paid in
stock and warrants 1,015 -
Compensatory element of stock issuances 1,735 1,533
Stock issued for professional services 339 237
Amortization of unearned license revenue ( 1,170) ( 1,170)
License fee - 9,000
(Increase) decrease in operating assets, net:
Accounts and notes receivable 883 163
Costs and estimated earnings in excess of
billings on uncompleted contracts 466 695
Inventories ( 978) ( 1,470)
Investment in sales-type lease - related parties - ( 935)
Principal payments received on investment
in sales type leases - related parties 30 52
Principal payments received on investment
in sales type leases 66 -
Prepaid expenses and other current assets ( 468) 123
Other assets 1 2
Advances and notes to related parties ( 1,265) 40
Increase (decrease) in operating liabilities, net:
Accounts payable ( 453) 537
Other current liabilities ( 135) ( 763)
Customer advances 1,327 ( 425)
Billings in excess of costs and estimated
earnings on uncompleted contracts 223 119
Other liabilities 21 -
Income taxes payable 12 -
-------- --------
Net cash provided by (used in) operating activities ( 4,056) 3,308
-------- --------
Cash Flows from Investing Activities:
Investment in marketable securities 14 1,936
Purchases of property and equipment ( 801) ( 1,243)
Costs of capitalized software development ( 354) -
-------- --------
Net cash provided by (used in) investing activities ( 1,141) 693
-------- --------
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(000'S OMITTED)
FOR THE SIX MONTHS ENDED
DECEMBER 31,
------------------------
2001 2000
-------- --------
Cash Flows from Financing Activities:
Distributions to holders of minority interests ( 167) ( 184)
Repayment of borrowings and capital
lease obligations ( 2,917) ( 1,693)
Purchase of common stock - ( 4)
-------- --------
Net cash used by financing activities ( 3,084) ( 1,881)
-------- --------
Increase (Decrease) in Cash ( 8,281) 2,120
Cash and Cash Equivalents - beginning of period 14,040 11,430
-------- --------
Cash and Cash Equivalents - end of period $ 5,759 $13,550
======== ========
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(000'S OMITTED)
FOR THE SIX MONTHS ENDED
DECEMBER 31,
------------------------
2001 2000
-------- --------
Net loss $(8,557) $(6,921)
Other comprehensive income, net of tax:
Unrealized gains (losses) on securities,
net of tax 66 227
-------- --------
Total comprehensive loss $(8,491) $(6,694)
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States ("US GAAP") for interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all of the information and footnotes required by US GAAP for
complete financial statements. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for a fair
presentation have been included. Operating results for the six-month period
ended December 31, 2001 are not necessarily indicative of the results that may
be expected for the year ending June 30, 2002. For further information, refer to
the consolidated financial statements and footnotes thereto included in the
Company's Annual Report on Form 10-K/A filed on October 30, 2001 for the fiscal
year ended June 30, 2001.
NOTE 2 - DESCRIPTION OF BUSINESS
FONAR Corporation (the "Company" or "FONAR") is a Delaware corporation, which
was incorporated on July 17, 1978. FONAR is engaged in the research,
development, production and marketing of medical scanning equipment which uses
principles of Magnetic Resonance Imaging ("MRI") for the detection and diagnosis
of human diseases. In addition to deriving revenues from the direct sale of MRI
equipment, revenue is also generated from its installed base of customers
through its service and upgrade programs.
Health Management Corporation of America ("HMCA") was organized by the Company
in March 1997 as a wholly-owned subsidiary in order to enable the Company to
expand into the business of providing comprehensive management services to
physicians' practices and other medical providers, including diagnostic imaging
centers and ancillary services. The services provided by the Company include
development, administration, leasing of office space, facilities and medical
equipment, provision of supplies, staffing and supervision of non-medical
personnel, legal services, accounting, billing and collection and the
development and implementation of practice growth and marketing strategies.
HMCA entered the physician and diagnostic management services business through
the consummation of two acquisitions, effective June 30, 1997, two acquisitions
which were consummated during fiscal 1998 and one acquisition consummated in
August of 1998. The acquired companies in all cases were actively engaged in the
business of managing medical providers. The medical providers are diagnostic
imaging centers, principally MRI scanning centers, multi-specialty practices and
primary care practices.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001 (UNAUDITED)
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
- ---------------------------
The consolidated financial statements include the accounts of FONAR Corporation,
its majority and wholly owned subsidiaries and partnerships. All significant
inter-company accounts and transactions have been eliminated in consolidation.
The Company no longer consolidates any medical practices which it manages. The
Company had previously consolidated certain medical practices managed as a
result of the 1998 acquisitions of A & A Services, Inc. and Dynamic Health Care
Management, Inc. The Company also previously consolidated the practices
conducted by Superior Medical Services, P.C. The Company has determined that
consolidation of such medical practices is not appropriate because the
underlying management agreements do not meet all of the six criteria of Emerging
Issue Task Force ("EITF") Consensus No. 97-2. Accordingly the consolidating
statement of operations and cash flows for the six-months ended December 31,
2000 have been restated. The significant effect of such restated financial
statements for the six months ended December 31, 2000 has been to decrease
revenue and related costs by $2.5 million. In addition, the consolidated balance
sheet caption "Excess of Costs Over Net Assets of Businesses Acquired - Net" has
been reclassified to "Management Agreements - Net".
Net revenue from the Company's wholly owned Florida multi-specialty practice is
reflected in the accompanying Consolidated Statement of Operations under the
caption "Patient - Net". Net revenue from the management of related medical
practices is reflected in the accompanying consolidated statements of operations
under the caption "Management and Other Fees - Related Medical Practices - Net".
Use of Estimates
- ----------------
The preparation of the consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities in the consolidated financial statements and accompanying notes.
The most significant estimates relate to contractual and other allowances,
income taxes, contingencies and the useful lives of equipment. In addition,
healthcare industry reforms and reimbursement practices will continue to impact
the Company's operations and the determination of contractual and other
allowance estimates. Actual results could differ from those estimates.
Inventories
- -----------
Inventories consist of purchased parts, components and supplies, as well as
work-in-process, and are stated at the lower of cost (determined on the
first-in, first out method) or market.
Management Agreements
- ---------------------
Management agreements are being amortized using the straight-line method over
20-year term of the agreements.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Long-Lived Assets
- -----------------
The Company periodically assesses the recoverability of long-lived assets,
including property and equipment, intangibles and management contracts, when
there are indications of potential impairment, based on estimates of
undiscounted future cash flows. The amount of impairment is calculated by
comparing anticipated discounted future cash flows with the carrying value of
the related asset. In performing this analysis, management considers such
factors as current results, trends, and future prospects, in addition to other
economic factors.
Earnings (Loss) Per Share
- -------------------------
Basic earnings (loss) per share is computed based on weighted average shares
outstanding and excludes any potential dilution. Diluted loss per share reflects
the potential dilution from the exercise or conversion of all dilutive
securities into common stock based on the average market price of common shares
outstanding during the period.
Options and warrants to purchase approximately 4,036,000 and 403,000 shares of
common stock were outstanding at December 31, 2001 and 2000, respectively, but
were not included in the computation of diluted earnings per share due to losses
in both periods, as a result of the options and warrants being antidilutive. In
addition, convertible debentures, which are convertible into 2,200,000 shares at
December 31, 2001 were antidilutive.
Stock-Based Compensation
- ------------------------
The Company accounts for its compensation and stock option plans in accordance
with the provisions of Accounting Principles Board ("APB") Opinion No. 25,
Accounting for Stock Issued to Employees, and related interpretations. As such,
compensation expense would be recorded on the date of grant only if the current
market price of the underlying stock exceeded the exercise price. In accordance
with SFAS No. 123, Accounting for Stock-Based Compensation, the Company provided
proforma net income and proforma earnings per share disclosures at June 30, 2001
for employee stock option grants, as if the fair-value-based method defined in
SFAS No. 123 had been applied.
Stock-based compensation issued to employees and consultants is valued based on
the quoted market price of the common stock at the time of issuance.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements
- --------------------------------
In July 2001, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial Accounting Standards No. 141 ("SFAS 141"), "Business Combinations"
which supersedes Accounting Principles Board ("APB") Opinion No. 16, "Business
Combinations". SFAS 141 requires the purchase method of accounting for business
combinations initiated after June 30, 2001 and eliminates the
pooling-of-interests method. In addition, SFAS 141 establishes specific criteria
for the recognition of intangible assets separately from goodwill and requires
unallocated negative goodwill to be written off immediately as an extraordinary
gain. The provisions of SFAS 141 have been adopted by the Company as of July 1,
2001. The adoption of SFAS 141 has not changed the method of accounting used in
previous business combinations, initiated prior to July 1, 2001.
In July 2001, the FASB also issued Statement of Financial Accounting Standards
No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets," which is effective
for fiscal years beginning after December 15, 2001. Certain provisions may also
apply to acquisitions initiated subsequent to June 30, 2001. SFAS 142 supersedes
APB Opinion No. 17 "Intangible Assets" and requires, among other things, the
discontinuance of amortization related to goodwill and indefinite lived
intangible assets. These assets will then be subject to an impairment test at
least annually. In addition, the standard includes provisions upon adoption for
the reclassification of certain existing recognized intangible as goodwill,
reassessment of the useful lives of existing recognized intangibles and
reclassification of certain intangibles out of previously reported goodwill. The
Company does not anticipate any significant impact to the consolidated financial
statements as the result of the adoption of SFAS No. 142 and expects to continue
to amortize all identifiable intangible assets.
In October 2001, the FASB issued Statement of Financial Accounting Standards No.
144 ("SFAS 144"), Accounting for the Impairment or Disposal of Long-Lived
Assets," which supersedes Statement of Financial Accounting standards No. 121
("SFAS 121), "Accounting for the Impairment of Long-Lived Assets and for Long-
Lived Assets to be Disposed Of" and certain provisions of APB Opinion No. 30,
"Reporting Results of Operations-Reporting the Effects of Disposal of a Segment
of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and
Transactions". SFAS 144 requires that long-lived assets to be disposed of by
sale, including discontinued operations, be measured at the lower of carrying
amount or fair value less cost to sell, whether reported in continuing
operations or in discontinued operations. SFAS 144 also broadens the reporting
requirements of discontinued operations to include all components of an entity
that have operations and cash flows that can be clearly distinguished,
operationally and for financial reporting purposes, from the rest of the entity.
The provisions of SFAS 144 are effective for fiscal years beginning after
December 15, 2001. The Company is evaluating the effect of this statement on the
Company's results of operations and financial position.
Reclassifications
- -----------------
Certain prior year balances have been reclassified to conform to the current
year presentation.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 4 - CASH AND CASH EQUIVALENTS
The Company considers all short-term highly liquid investments with a maturity
of three months or less when purchased to be cash or cash equivalents. At
December 31, 2001, the Company had cash deposits of approximately $5.3 million
in excess of federally insured limits.
NOTE 5 - RESTRICTED CASH
At December 31, 2001, $5,500,000 of cash has been pledged as collateral on an
outstanding bank loan and has been classified as restricted cash on the
consolidated balance sheet.
NOTE 6 - MARKETABLE SECURITIES
- -------------------------------
The following is a summary of marketable securities at December 31, 2001:
(000's omitted)
---------------
Unrealized
Amortized Holdings Fair Market
Cost Gains Value
--------- ----------- -----------
U.S. Government $3,864 $ 107 $3,971
obligations
Corporate bonds 2,123 43 2,166
--------- ----------- -----------
$5,987 $ 150 $6,137
========= =========== ===========
NOTE 7 - ACCOUNTS RECEIVABLE, NET
Accounts receivable, net is comprised of the following at December 31, 2001:
(000's omitted)
---------------
Allowance for
doubtful accounts
Gross and contractual
Receivable allowances Net
---------- ----------------- --------
Receivable from equipment
sales and service contracts $ 2,096 $ 1,033 $1,063
========= ========= ========
Receivables from related PCs $13,120 $1,035 $12,085
========= ========= ========
The Company's customers are concentrated in the healthcare industry.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 7 - ACCOUNTS RECEIVABLE, NET (Continued)
The Company's receivables from the related PC's substantially consist of fees
outstanding under management agreements, service contracts and lease agreements
with related PC's. Payment of the outstanding fees is based on collection by the
PC's of fees from third party medical reimbursement organizations, principally
insurance companies and health management organizations.
Collection by the Company of its accounts receivable may be impaired by the
uncollectibility of medical fees from third party payors, particularly insurance
carriers covering automobile no-fault and workers compensation claims due to
longer payment cycles and rigorous informational requirements. Approximately 56%
and 40% of the PC's net revenues for the six months ended December 31, 2001 and
December 31, 2000, respectively, were derived from no-fault and personal injury
protection claims. The Company considers the aging of its accounts receivable in
determining the amount of allowance for doubtful accounts and contractual
allowances. The Company takes all legally available steps, including legally
prescribed arbitrations, to collect its receivables. Credit losses associated
with the receivables are provided for in the consolidated financial statements
and have historically been within management's expectations.
Net revenues from the related PC's, including product sales, accounted for
approximately 81% and 78% of the consolidated net revenues for the six months
ended December 31, 2001 and 2000, respectively.
Unaudited Financial Information of Unconsolidated Managed Medical Practices
- ---------------------------------------------------------------------------
Summarized income statement data for the six months ended December 31, 2001
related to the 24 unconsolidated medical practices managed by the Company is as
follows:
(000's omitted)
Patient Revenue - Net $17,076
========
Income from Operations $ 131
========
Net Income $ 41
========
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 8 - INVENTORIES
Inventories included in the accompanying consolidated balance sheets consist of:
l (000's omitted)
December 31, 2001 June 30, 2001
----------------- -------------
Purchased parts, components
and supplies $3,856 $3,050
Work-in-process 847 675
-------- ---------
$4,703 $3,725
======== =========
NOTE 9 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER
ADVANCES
(000's omitted)
1) Information relating to uncompleted contracts as of December 31, 2001 is as
follows:
Costs incurred on uncompleted $4,505
contracts
Estimated earnings 1,103
--------
5,608
Less: Billings to date 4,879
--------
$ 729
========
Included in the accompanying consolidated balance sheet under the following
captions:
Costs and estimated earnings in
excess of billings on
uncompleted contracts $1,303
Billings in excess of costs and
estimated earnings on
uncompleted contracts 574
--------
$ 729
========
2) Customer advances consist of the following:
Total advances from customers $7,878
Less: Advances from customers
on contracts under
construction 4,879
--------
$2,999
========
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 10 - CONVERTIBLE DEBENTURES
Pursuant to a securities purchase agreement, dated May 24, 2001, between the
Company and an investor group, the Company issued and sold to the investor group
on that date for an aggregate purchase price of $4.5 million:
4% convertible debentures due June 30, 2002 in the aggregate principal amount of
$4.5 million, convertible into shares of the Company's common stock at a
conversion price of $2.047 per share, subject to adjustment.
Purchase warrants to purchase an aggregate of 659,501 shares of the Company's
common stock at an initial exercise price of $1.801 per share, subject to
adjustment; and
Callable warrants to purchase an aggregate of 2,000,000 shares of the Company's
common stock at a fluctuating exercise price which will vary depending on the
market price for the Company's common stock.
In connection with the issuance of the debentures, the Company paid a placement
fee in the amount of $157,500. In addition, the Company issued 300,000 purchase
warrants to the placement agent.
The debentures are convertible at the option of the holder at a price of $2.047
per share. If the holders decide not to convert, the debenture is payable in ten
monthly installments of $450,000 commencing September 1, 2001. At the option of
the Company, the principal installments can be either in cash or shares of the
Company's' common stock, valued at the lesser of: a) 90% of the average of the
four lowest closing bid prices during the preceding month, or b) the average of
the four lowest closing bid prices during the preceding calendar month, less
$0.125. By amendment dated October 25, 2001, however, the payments originally
due October 1, 2001 and November 1,
2001, were extended to November 5, 2001, and for those payments, the stock was
valued at the average of the two lowest closing bid prices for October, 2001
less $0.25. On November 5, 2001, the Company made these payments for principal
due of $900,000 and related accrued interest on this principal of $16,500
through the issuance of 959,626 shares of the Company's common stock. The
Company made the December, 2001, January, 2002 and February, 2002 payments
($450,000 plus interest each) through the issuance of 398,181 shares, 430,935
shares and 486,895 shares.
The purchase warrants cover 959,501 shares of common stock and have an exercise
price of $1.801 per share, subject to adjustment. The exercise period extends to
May 24, 2006.
The callable warrants cover 2,000,000 shares of common stock and have a variable
exercise price. Subject to a maximum price of $6.00 per share and a minimum
price of $2.00 per share, which is subject to adjustment, pursuant to the terms
of the warrants, the exercise price will be equal to the average closing bid
price of the Company's common stock for the full calendar month preceding the
date of exercise. The exercise period extends to May 24, 2004.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 10 - CONVERTIBLE DEBENTURES (Continued)
The Company has the option of redeeming up to 200,000 callable warrants per
month at a price of $0.01 per underlying warrant share, if the average closing
bid price of its common stock is greater than 115% of the warrant price in
effect for five consecutive trading days in any calendar month.
The debentures and warrants provide for proportionate adjustments in the event
of stock splits, stock dividends and reverse splits. In addition, the conversion
and exercise prices will be reduced, with certain specified exemptions, if the
Company issues shares at lower prices, then the debenture conversion or warrant
exercise prices, or less than market price for the common stock.
The terms of the registration rights agreement with the investor requires the
Company to register approximately two times the number of shares necessary to
repay the debentures in common stock at the lower of the market price, as
computed under the agreement, or the conversion price, plus the number of shares
underlying the warrants.
NOTE 11 - NOTES PAYABLE
Pursuant to a stock payment agreement consummated in January, 2002 between the
Company and Dr. Glenn Muraca and Dr. Giovanni Marciano, Dr. Muraca and Dr.
Marciano agreed to accept payment of certain debt obligations in shares of
common stock and the Company issued 1,000,000 shares of common stock to each of
them, or 2,000,000 shares in the aggregate. The shares are being issued to pay
four promissory notes which were issued by our subsidiary, HMCA, in partial
payment of the purchase price for the acquisition of A&A Services, Inc. The
total balance of principal and interest due under the notes as of December 20,
2001 was $3,076,791.20. Payments under the notes were due quarterly. In order to
induce Dr. Muraca and Marciano to accept payment in stock and in the manner
provided in the stock payment agreement, the Company agreed to pay a premium on
the note obligations. The total amount now due as a result is $3,613,325.50 in
the aggregate.
Under the terms of the stock payment agreement, Company will issue shares, and
the net proceeds from the sale of the shares will be applied to the
indebtedness. The quarterly payment due dates were waived, but the net proceeds
received by the selling stockholders must be sufficient to pay the full
indebtedness for each note, including the premium on the note, by the final
maturity date of the note: September 20, 2002 in the case of two of the notes
and December 20, 2002 in the case of two of the notes. If a note, including the
premium, is not satisfied in full by the time of its final maturity date, then
interest will accrue on the unpaid balance at the rate of 6% per annum and the
selling stockholders could require the difference to be paid in cash.
In the event the net proceeds from the sale of the 2,000,000 shares issued are
not sufficient to pay the obligations by July 1, 2002, the Company will issue
additional shares in an amount estimated to be sufficient to pay the balance
due. The Company has reserved the option not to issue more than 5,000,000 shares
in the aggregate. This transaction will increase the liquidity of the Company by
making cash available for other purposes.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 12 - SUPPLEMENTAL CASH FLOW INFORMATION
During the six months ended December 31, 2001 and 2000, the Company paid
approximately $428,000 and $480,000 for interest, respectively. During the six
months ended December 31, 2001 and 2000, the Company paid approximately $0 and
$28,000 for income taxes, respectively.
During the six months ended December 31, 2001:
The Company issued 234,083 shares of common stock for professional services of
$338,563.
The Company issued 579,015 shares of common stock to employees as compensation
of $910,094 under stock bonus plans.
c) The Company issued 231,295 shares of common stock for consulting services
of $343,038.
d) The Company issued 1,367,867 shares of common stock in satisfaction of
principal of $1,350,000 and accrued interest of $26,100.
During the six months ended December 31, 2000:
a) The Company issued 418,708 shares of common stock to employees as
compensation of $885,538 under stock bonus plans.
b) The Company issued 636,767 shares of common stock for consulting services
of $1,244,201.
c) The Company acquired equipment of $56,831 under an equipment note payable
obligation.
d) The Company issued 124,000 shares of common stock for professional services
of $234,000.
NOTE 13 - SALE OF SUBSIDIARY
In June of 2001, HMCA sold the stock of its wholly-owned Florida multi-specialty
practice subsidiaries, Medical Specialties, Inc. and Diagnostic Services, Inc.
for a promissory note for $50,000, resulting in a loss of $37,000.
NOTE 14 - SEGMENT AND RELATED INFORMATION
Effective July 1, 1998, the Company adopted the provisions of SFAS No. 131,
"Disclosures About Segments of an Enterprises and Related Information". SFAS No.
131 establishes standards for the way public enterprises report information
about operating segments in annual financial statements and requires those
enterprises to report selected information about operating segments in interim
financial reports issued to stockholders.
The Company operates in two industry segments - manufacturing and the servicing
of medical equipment and management of physician practices, including diagnostic
imaging services.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2001
(UNAUDITED)
NOTE 14 - SEGMENT AND RELATED INFORMATION (Continued)
The accounting policies of the segments are the same as those described in the
summary of significant accounting policies as disclosed in the Company 10-K/A as
of June 30, 2001. All inter- segment sales are market-based. The Company
evaluates performance based on income or loss from operations.
Summarized financial information concerning the Company's reportable segments is
shown in the following table: (000's omitted)
Physician
Medical Management
Equipment Services Total
--------- ---------- --------
For the six months ended December 31, 2001:
Net revenue from external customers 6,263 13,657 19,920
Inter-segment net revenues 578 - 578
Operating (loss) income (7,971) 559 (7,412
Depreciation and amortization 1,279 1,288 2,567
Compensatory element of stock
issuances 854 881 1,735
Total identifiable assets 40,434 36,090 76,524
Capital expenditures 516 285 801
For the six months ended December 31, 2000:
Net revenue from external customers 3,429 15,142 18,571
Inter-segment net revenues 551 - 551
Operating (loss) income (9,258) 1,300 (7,958
Depreciation and amortization 1,097 1,226 2,323
Compensatory element of stock 792 741 1,533
issuances
Total identifiable assets 46,756 41,365 88,121
Capital expenditures 827 416 1,243
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS
OF OPERATIONS.
For the fiscal quarter ended December 31, 2001 (second quarter of fiscal
2002), the Company reported a net loss of $4.7 million on revenues of $9.8
million as compared to a net loss of $3.0 million on revenues of $9.6 million
for the second quarter of fiscal 2001.
For the six month period ended December 31, 2001, the Company reported a
net loss of $8.6 million on revenues $19.9 million, as compared to a net loss of
$6.9 million on revenues of $18.6 million for the six month period ended
December 31, 2000.
The Company operates in two industry segments: the manufacture and
servicing of medical (MRI) equipment, the Company's traditional business which
is conducted directly by Fonar and physician and diagnostic management services,
which is conducted through Fonar's wholly-owned subsidiary, Health Management
Corporation of America ("HMCA").
Increased MRI equipment sales resulted in an increase in revenues
recognized by the Company's MRI equipment manufacturing and service business,
from $3.4 million in the first six months of fiscal 2001 to $6.3 million in the
first six months of fiscal 2002. A significant increase in scanner sales to
related parties, from $118,000 in the first six months of fiscal 2001 to $2.4
million in the first six months of fiscal 2002, was the principal reason for the
increase. As a result the operating loss from the Company's MRI equipment
manufacturing and service business was $8.0 million for the six months of fiscal
2002 as compared to $9.3 million for the first six months of fiscal 2001.
HMCA (physician and diagnostic management services) income from operations
was $559,000 for the first six months of fiscal 2002 compared to income of $1.3
million for the first six months of fiscal 2001. The decline in HMCA income was
attributable to lower revenues reflecting a decline in management fees ($13.7
million for the first six months of fiscal 2002 compared to $15.1 million for
the first six months of fiscal 2001) from the medical practices managed by HMCA.
During the second quarter of fiscal 2002, two of the MRI scanning facilities
managed by HMCA were closed, contributing to the decline in revenues.
Accordingly the Company's consolidated operating loss was $7.4 million for
the first six months of fiscal 2002 as compared to a consolidated operating loss
of $8.0 million for the first six months of fiscal 2001.
Although the Company's scanner sales increased significantly from fiscal
2001, low product sales volume continues to be the principal reason for the
Company's operating losses. Sales revenues attributable to the Company's medical
(MRI) equipment business were $3.9 million for the first six months of fiscal
2002 as compared to $1.3 million for the first six months of fiscal 2001. Costs
of revenues attributable to the Company's product sales were $3.0 million for
the six months of fiscal 2002 as compared to $1.8 million for the first six
months of fiscal 2001.
The Company's efforts to improve equipment sales volume have emphasized
research and development to improve the competitiveness of its products and
increased marketing and sales efforts. Research and development expenditures
were $2.5 million for the first six months of fiscal 2002 and $3.0 million for
the first six months of fiscal 2001.
Selling, general and administrative expenses increased, from $9.2 million
in the first six months of fiscal 2001 to $9.8 million in the first six months
of fiscal 2002, primarily due to the expansion of Fonar's sales force and
efforts (an increase of approximately $460,000) and the amortization of deferred
financing costs of $148,000 during fiscal 2002 incurred in connection with the
issuance of convertible debentures in the principal amount of $4.5 million in
May 2001.
The increase in compensatory element of stock issuance from approximately
$1.5 million for the first six months of fiscal 2001 to approximately $1.7
million for the first six months of fiscal 2002 reflected greater use of Fonar's
stock bonus plan to pay certain employees in stock rather than cash.
Interest expense ($562,000) in the first six months of fiscal 2002 as
compared to $594,000 for the first six months of fiscal 2001) remained constant.
Financing costs paid in shares of stock and warrants, however, in the amount of
$1.0 million, were incurred in the first six months of fiscal 2002, reflecting
the amortization of the value of the warrants issued in connection with issuance
of the Company's convertible debentures ($588,000) and financing costs in
connection with the Company's convertible debentures ($427,000).
Inventories increased to $4.7 million at December 31, 2001 from $3.7
million at June 30, 2001 as the Company purchased parts and commenced
manufacturing scanners to fill orders and anticipated orders.
Accounts receivable increased to $1.1 million as at December 31, 2001 from
$850,000 as at June 30, 2001, principally reflecting increased revenues from
service contracts on MRI scanners.
The Company's Indomitable (TM) (also referred to as Stand-Up), QUAD (TM),
Fonar-360 (TM) and QUAD 12000S (TM) MRI, are intended to significantly improve
the Company's competitive position. In addition, the Company offers a low cost
open scanner, the Echo (TM) MRI, operating at .3 Tesla field strength.
The Company's Indomitable (TM) scanner allows patients to be scanned while
standing or reclining. As a result, for the first time, MRI is able to be used
to show abnormalities and injuries under full weight-bearing conditions,
particularly the spine and joints. A floor-recessed elevator brings the patient
to the height appropriate for the targeted image region. A custom-built
adjustable bed allows patients to sit or lie on their backs, sides or stomachs
at any angle. Full-range-of-motion studies of the joints in virtually any
direction will be possible, an especially promising feature for sports injuries.
The Company believes that Indomitable(TM) will also prove useful for
MRI-directed surgical procedures as the surgeon would have unhindered access to
the patient with no restrictions in the vertical direction. This easy-entry,
mid-field-strength scanner should be ideal for trauma centers where a quick
MRI-screening within the first critical hour of treatment will greatly improve
patients' chances for survival and optimize the extent of recovery.
The Fonar 360 has an enlarged room sized magnet in which the magnet frame
is incorporated into the floor, ceiling and walls of the scan room. This is made
possible by Fonar's patented Iron-Frame(TM) technology which allows the
Company's engineers to control, contour and direct the magnet's lines of flux in
the patient gap where wanted and almost none outside of the steel of the magnet
where not wanted. Physicians and family members are able to actually enter the
scanner and approach the patient. In its Open Sky version, the Fonar 360 serves
as an open patient friendly scanner which allows 360 degree access to the
patient on the scanner bed. The walls can be decorated with panoramic murals and
the entire scan room can be decorated to be incorporated into the pictured
landscape.
In its future interventional OR-360 version, the enlarged room sized magnet
and 360 degree access to the patient afforded by the Fonar 360 permit
full-fledged surgical teams to walk into the magnet and perform surgery on the
patient inside the magnet. Most importantly the exceptional quality of the MRI
image and its exceptional capacity to exhibit tissue detail on the image, by
virtue of the nuclear resonance signal's extraordinary capacity to create image
contrast, can then be obtained real time during surgery to guide the surgeon in
the surgery. Thus surgical instruments, needles, catheters, endoscopes and the
like can be introduced directly into the human body and guided to the malignant
lesion by means of the MRI image. The number of inoperable lesions should be
greatly reduced by the availability of this new capability. Most importantly
treatment can be carried directly to the target tissue.
The "QUAD" scanners are unique MRI scanners in that four sides are open
thus allowing access to the scanning area from four vantage points. The
starshaped open design of the QUAD will also make possible a host of new
applications, particularly MRI mammography and MRI directed surgery
(Interventional MRI). The QUAD (TM) 12000 MRI scanner utilizes a 6000 gauss iron
core electromagnet and is accessible from four sides. The QUAD 12000 is the
first "open" MRI scanner at high field.
The Company also offers a low cost open scanner, the Echo, which operates
at a .3 Tesla field strength. The Echo is an open upgraded version of the
Company's former principal product, the Beta MRI scanner, but is open on four
sides to provide four directions for patient access instead of two.
The Company has also developed a superconductive version of its open iron
frame magnets, the "QUAD 12000S" (TM), and has completed construction of a
prototype with a 0.6 Tesla superconductive magnet. The Company's design of its
superconductive magnet anticipated the possibility of making its other products
available as superconducting magnets. Therefore, it is the Company's objective
to make Indomitable (TM) and the Fonar 360 available to FONAR's customers as
either iron-frame resistive models or iron-frame superconductive magnets
depending on customer preference and pricing.
During the first six months of fiscal 2002, revenues of approximately $3.9
million were recognized from the sale of Stand-Up MRI scanners and $48,000 from
the sale of QUAD MRI scanners. In addition, revenues of approximately $180,000
were recognized from the sales of upgrades, principally from the Sympulse (TM)
upgrade.
During the first six months of fiscal 2001, revenues of approximately
$118,000 were recognized from the sale of QUAD scanners, $892,000 from the sale
of the Stand-Up MRI scanners and, $51,000 from the sale of Echo scanners
There were no foreign product sales for the first six months of fiscal 2002
or fiscal 2001.
Liquidity and Capital Resources.
Cash and cash equivalents decreased from $14.0 million at June 30, 2001 to
$5.8 million at December 31, 2001. Principal uses of cash during the first three
months of fiscal 2002 included: capital expenditures of $1.2 million, repayment
of long-term debt of $2.9 million and $4.1 million to fund operating activities
for the first six months of fiscal 2002.
Marketable securities approximated $6.1 million as of both December 31,
2001 and June 30, 2001. Such investments were in U.S. government obligations and
corporate bonds.
Total liabilities decreased since June 30, 2001 by $4.5 million to $38.4
million at December 31, 2001. The decrease in liabilities from June 30, 2001 is
attributable primarily to the repayment of long-term debt and capital lease
obligations of $2.9 million and the amortization of the license fee of $1.2
million.
As of December 31, 2001, the Company had a bank credit facility of
$5,500,000. The unused portion of the facility was approximately $214,000. The
interest on loans made under the facility is either the bank's prime rate, as in
effect from time to time, or 0.5% plus the bank's cost of funds rate, as
selected by Fonar when the loan is made.
The Company's business plan currently includes an aggressive program for
manufacturing and selling its new line of scanners and expanding its new
physician and diagnostic management services business.
In May of 2001, the Company issued convertible debentures in the principal
amount of $4.5 million. These debentures are convertible at the option of the
holder at a price of $2.047 per share. Otherwise, the debentures are payable in
ten monthly installments of principal of $450,000 each, with interest at 4% per
annum. The installments can be paid in cash or common stock at the Company's
option. In such case the common stock would be valued at the lesser of: a) 90%
of the average of the four lowest closing bid prices during the preceding month,
or b) the average of the four lowest closing bid prices during the preceding
calendar month, less $0.125. By amendment dated October 25, 2001, however, the
payments originally due October 1, 2001 and November 1, 2001, were extended to
November 5, 2001, and for those payments, the stock was valued at the average of
the two lowest closing bid prices for October, 2001 less $0.25. On November 5,
2001, the Company made these payments for principal due of $900,000 and related
accrued interest on this principal of $16,500 through the issuance of 959,626
shares of the Company's common stock. The Company made the December, 2001,
January, 2002 and February, 2002 payments ($450,000 plus interest each) through
the issuance of 398,181 shares, 430,935 shares and 486,895 shares.
No part of the debentures have been converted to date. The ability of the
Company to pay this debt in common stock increases the liquidity of the Company
by enabling cash to be used for operations and to pay other obligations.
Pursuant to a stock payment agreement consummated in January, 2002 between
the Company and Dr. Glenn Muraca and Dr. Giovanni Marciano, Dr. Muraca and Dr.
Marciano agreed to accept payment of certain debt obligations in shares of
common stock and the Company issued 1,000,000 shares of common stock to each of
them, or 2,000,000 shares in the aggregate. The shares are being issued to pay
four promissory notes which were issued by our subsidiary, Health Management
Corporation of America or HMCA, in partial payment of the purchase price for the
acquisition of A&A Services, Inc. The total balance of principal and interest
due under the notes as of December 20, 2001 was $3,076,791.20. Payments under
the notes were due quarterly. In order to induce Dr. Muraca and Marciano to
accept payment in stock and in the manner provided in the stock payment
agreement, the Company agreed to pay a premium on the note obligations. The
total amount now due as a result is $3,613,325.50 in the aggregate.
Under the terms of the stock payment agreement, Company will issue shares,
and the net proceeds from the sale of the shares will be applied to the
indebtedness. The quarterly payment due dates were waived, but the net proceeds
received by the selling stockholders must be sufficient to pay the full
indebtedness for each note, including the premium on the note, by the final
maturity date of the note: September 20, 2002 in the case of two of the notes
and December 20, 2002 in the case of two of the notes. If a note, including the
premium, is not satisfied in full by the time of its final maturity date, then
interest will accrue on the unpaid balance at the rate of 6% per annum and the
selling stockholders could require the difference to be paid in cash.
In the event the net proceeds from the sale of the 2,000,000 shares issued
are not sufficient to pay the obligations by July 1, 2002, the Company will
issue additional shares in an amount estimated to be sufficient to pay the
balance due. The Company has reserved the option not to issue more than
5,000,000 shares in the aggregate. This transaction will increase the liquidity
of the Company by making cash available for other purposes.
The Company believes that it has sufficient cash resources and other liquid
assets to support its operations. The Company and its subsidiary, HMCA, are
continuing to explore both bank financing and the placement of debt and equity
securities.
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings:
There were no material changes in litigation for the first six months of
fiscal 2002 from that described in the Company's Form 10-K for the fiscal year
ended June 30, 2001.
Item 2 - Changes in Securities: None
Item 3 - Defaults Upon Senior Securities: None
Item 4 - Submission of Matters to a Vote of Security Holders: None
Item 5 - Other Information: None
Item 6 - Exhibits and Reports on Form 8-K: None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
FONAR CORPORATION
(Registrant)
By: /s/ Raymond V. Damadian
Raymond V. Damadian
President, Chairman
Chief Executive Officer and
Acting Principal Financial Officer
Dated: February 15, 2002